ASTH at a glance
Astrana Health, Inc. (ASTH, SEC CIK 1083446) filed its latest 10-K annual report on March 12, 2026, a 10-Q quarterly report on August 10, 2026, an 8-K current report on September 23, 2026 and Form 4 insider filings as recently as October 6, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Astrana Health, Inc. (ASTH) reported revenue of $3.2 billion (up 56.4% from FY2024) and net income of $22.5 million. Diluted EPS was $0.46.
- As of June 30, 2026, 27 institutional investment managers tracked by SignalX reported holding Astrana Health, Inc. (ASTH) shares worth $927.6 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $3.2B
- +56.4% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 27 funds
- $927.6M · −1 vs prior quarter
- Latest 8-K
- Sep 23, 2026
- Item 1.05
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business: Physician-centric, technology-powered, risk-bearing healthcare platform focused on value-based care delivery and coordination for 1.6 million patients
- New emphasis on expanded Care Enablement segment integrating clinical, operational, financial, and administrative data via proprietary technology suite
- Strategic shift to assume full financial risk through California Restricted Knox-Keene licensed health plans (RKKs) for broader professional and institutional risk management
- Workforce growth stable with approximately 3,000 employees as of December 31, 2025, supporting over 20,000 contracted physicians in integrated network
- Noteworthy expansion of employee development programs and increased community engagement including donations and volunteerism in 2025
Management Discussion & Analysis
- Revenue $3.18B in 2025, up $1.15B vs $2.03B in 2024, ~56% YoY growth driven by acquisitions and organic growth
- Adjusted EBITDA $205.4M, up from $170.4M in 2024, margin decreased to 6% from 8% YoY
- Best segment: Prospect acquisition contributed significantly; worst unclear due to consolidated data only
- Free cash flow $104.5M vs $44.2M prior year; $15.4M share repurchases, $7.9M dividends, $10.1M capex in 2025
- Management highlights liquidity with $429.5M cash, $1.05B total debt, completed Prospect acquisition funded by $707.3M drawdown; sees sufficient liquidity for next 12 months
AI summary of the ASTH 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Revenue $972.5M, up 49% YoY from $654.8M, including $281.5M from Prospect acquisition
- Operating margin 3.5% vs 3.1% YoY; net income attributable to Astrana $19.7M vs $9.4M
- Adjusted EBITDA $68.9M, up 43% YoY from $48.1M
- Prospect strongest contributor, adding $281.5M revenue; APC weakest, generating $1.3M non-controlling-interest loss
- Borrowings $948.3M vs $408.9M YoY; interest expense $16.0M, up 117% to fund Prospect acquisition
Risk Factors
- No material changes in risk factors from the December 31, 2025 Form 10-K
- Carried-forward healthcare-industry and company-specific risks potentially affecting operations, cash flows, and stock price
- Unknown or currently immaterial risks could materially adversely affect business performance
- Historical financial performance unreliable as an indicator of future results
AI summary of the ASTH 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 1.05: Material Cybersecurity Incidents
- Forward-looking disclosures concern a cybersecurity incident, including impact assessment, containment, remediation, and investigation
- Potential exposure includes unauthorized data release, operational disruption, regulatory scrutiny, litigation, reputational damage, and remediation costs
Item 7.01: Regulation FD Disclosure
- Updated corporate presentation for conference and meeting use, signaling refreshed investor messaging
- Exhibit 99.1 contains the substantive presentation materials and may include updated strategy or operating information
Item EX-99.1: Item EX-99.1
- FY2026 revenue guidance $3.8–4.1B and Adjusted EBITDA guidance $255–280M, midpoint $267.5M
- 2026E Adjusted EBITDA margin 6.8%, with targeted mid-to-high teens annual growth over the medium term
Item 7.01: Regulation FD Disclosure
- Updated corporate presentation dated September 15, 2026 for conference and investor meetings
- Exhibit 99.1 contains the substantive company disclosures and presentation materials
Item EX-99.1: Item EX-99.1
- FY2026 revenue guidance of $3.8–4.1B, implying continued rapid scale from $3.18B in FY2025
- Adjusted EBITDA guidance raised to $255–280M, above $205.4M in FY2025
AI summaries of ASTH 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for ASTH
Don't miss the next ASTH filing
- Alerts as it files. A push when ASTH files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut ASTH, by share count.
- Ask anything. An AI agent that reads every ASTH filing and answers with sources.
ASTH alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Basho Chandan | F | Oct 2, 2026 | 2,092 | $35.88 |
| Vong John | F | Sep 15, 2026 | 96 | $38.35 |
| Sim Brandon | F | Sep 5, 2026 | 7,163 | $38.47 |
| Basho Chandan | F | Sep 5, 2026 | 1,790 | $38.47 |
| Kitayama Mitchell W | D | Aug 31, 2026 | 8,500 | $37.09 |
| Schmidt David | M | Aug 14, 2026 | 20,000 | $5.00 |
| Schmidt David | D | Aug 14, 2026 | 20,000 | $38.59 |
| Schmidt David | M | Aug 14, 2026 | 20,000 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $2.0B | $3.2B |
| Operating Income | - | $89.3M | $78.5M |
| Net Income | $60.7M | $43.1M | $22.5M |
| Op. Margin | - | 4.4% | 2.5% |
| Net Margin | - | 2.1% | 0.7% |
| Balance Sheet | |||
| Total Assets | $933.4M | $1.4B | $2.2B |
| Equity | - | $712.7M | $779.3M |
| ROE | - | 6.1% | 2.9% |
| Per Share | |||
| EPS | $1.29 | $0.90 | $0.46 |
| Cash Flow | |||
| Operating CF | - | $52.2M | $114.6M |
| CapEx | $28.5M | $8.0M | $10.1M |
Source: XBRL data in Astrana Health, Inc. (ASTH)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate ASTH share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 27 | $927.6M |
| Q1 2026 | 28 | $420.1M |
| Q4 2025 | 28 | $441.4M |
| Q3 2025 | 28 | $517.9M |
| Q2 2025 | 26 | $440.6M |
| Q1 2025 | 22 | $372.0M |
| Q4 2024 | 19 | $325.6M |
| Q3 2024 | 18 | $265.8M |
- BlackRock+736.3K (+12%)
- Wells Fargo & Co+561.9K (+546%)
- Vanguard Portfolio Management LLC+329.0K (+14%)
- Bank of America Corp+277.4K (+48%)
- FMR LLC (Fidelity)+269.8K (+65%)
- Ameriprise Financial−39.5K (-7%)
- Renaissance Technologies LLC−29.9K (-29%)
- Goldman Sachs Group−23.5K (-8%)
- AQR Capital Management−16.8K (-49%)
- Franklin Resources−16.4K (-68%)
- Truist Financial−10.0K
Source: 13F-HR filings on SEC EDGAR (aggregated from 196 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
ASTH filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Oct 6, 2026 | - | - | - |
| 8-K | Sep 23, 2026 | - | Analysis | - |
| 8-K | Sep 23, 2026 | - | Analysis | - |
| 4 | Sep 17, 2026 | - | - | - |
| 8-K | Sep 15, 2026 | - | Analysis | - |
| 4 | Sep 9, 2026 | - | - | - |
| 4 | Sep 8, 2026 | - | - | - |
| 4 | Sep 1, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 4 | Aug 11, 2026 | - | - | - |
| 10-Q | Aug 10, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| SC 13G | Jul 31, 2026 | - | - | |
| 8-K | Jul 13, 2026 | - | Analysis | - |
| 8-K | Jul 1, 2026 | - | Analysis | - |
| 4 | Jun 30, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 8-K | Jun 10, 2026 | - | Analysis | |
| 8-K | May 12, 2026 | - | Analysis | |
| 8-K | May 12, 2026 | - | Analysis |
Related Health Care companies
- TXG · 10x Genomics, Inc.Laboratory Analytical Instruments
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ABSI · Absci CorpServices-Commercial Physical & Biological Research
- ACHC · Acadia Healthcare Company IncServices-Specialty Outpatient Facilities, NEC
ASTH SEC filings: frequently asked questions
Which institutions hold ASTH stock?
As of June 30, 2026, the largest Astrana Health, Inc. (ASTH) holders among the 13F filers tracked by SignalX were BlackRock ($320.2 million), Vanguard Portfolio Management LLC ($120.9 million), Vanguard Capital Management LLC ($90.3 million), State Street Corp ($80.7 million), Dimensional Fund Advisors ($68.1 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was ASTH's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Astrana Health, Inc. (ASTH) reported revenue of $3.2 billion (up 56.4% from FY2024) and net income of $22.5 million. Diluted EPS was $0.46. The figures come from the XBRL data in the 10-K.
What did ASTH report in its latest 8-K?
Astrana Health, Inc. (ASTH) filed an 8-K on September 23, 2026 reporting Item 1.05 (Material Cybersecurity Incidents). Forward-looking disclosures concern a cybersecurity incident, including impact assessment, containment, remediation, and investigation.
What are the latest ASTH SEC filings?
Astrana Health, Inc. (ASTH) filed its latest 10-K annual report on March 12, 2026, a 10-Q quarterly report on August 10, 2026, an 8-K current report on September 23, 2026 and a Form 4 insider filing on October 6, 2026.
What is ASTH's SEC CIK number?
Astrana Health, Inc. (ASTH)'s SEC Central Index Key (CIK) is 1083446. EDGAR lists every ASTH filing under that number.
Ask anything about ASTH
The research agent reads ASTH's filings, financials, insider trades and 13F holders, then answers with sources.